TILT-123

Phase 1Biologic

TTILT Biotherapeutics Ltd.

TILT-123 is one of 90 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Ovarian CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

MelanomaPhase 1

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

Imjudo

AstraZeneca

Preclinical

5 3

Gilotrif

Boehringer Ingelheim

Preclinical

12 4

Ofev

Boehringer Ingelheim

Preclinical

7 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

REGN2810

1 10

TILT-123

TTILT Biotherapeutics Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Solid Tumors

NCT05222932

Q2 2027

Phase 1Active, not recruiting

Melanoma

NCT06961786

Q3 2027

Phase 1/2Recruiting

Ovarian Cancer

NCT05271318

Clinical

Trials by Indication[1]

Melanoma2 trials

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

Completed·TTILT Biotherapeutics Ltd.·Phase 1·NCT04217473·17 enrolled

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Active, not recruiting·TTILT Biotherapeutics Ltd.·Phase 1·NCT06961786·9 enrolled

Non-Small Cell Lung Cancer1 trial

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Active, not recruiting·TTILT Biotherapeutics Ltd.·Phase 1·NCT06125197·22 enrolled

Ovarian Cancer1 trial

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Recruiting·TTILT Biotherapeutics Ltd.·Phase 1/2·NCT05271318·29 enrolled

Solid Tumors1 trial

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Active, not recruiting·TTILT Biotherapeutics Ltd.·Phase 1·NCT05222932·15 enrolled

Monotherapy1 trial

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

Completed·TTILT Biotherapeutics Ltd.·Phase 1·NCT04695327·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for TILT-123. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TILT-123 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TILT-123. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TILT Biotherapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TTILT Biotherapeutics Ltd.

TILT-123

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Melanoma2 trials

Non-Small Cell Lung Cancer1 trial

Ovarian Cancer1 trial

Solid Tumors1 trial

Monotherapy1 trial

References

Drug Info

Quick Facts

Related News